Navigation Links
Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
Date:4/14/2008

the preferred partner to continue development, commercialize and market the drug. Isis will transition development responsibility for mipomersen to Genzyme over the next year. In addition to the up-front payment ($150 million for Isis stock at $30 per share and $175 million mipomersen license fee), Isis also has the opportunity to receive from Genzyme up to $825 million in development and regulatory milestone payments plus up to $750 million in commercial milestone payments. Genzyme and Isis will share mipomersen profits. The profit share begins with a 70/30 Genzyme/Isis split and increases linearly to 50/50 when revenue reaches $2 billion.

Mipomersen is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol. Cholesterol can be carried in the bloodstream in a variety of forms, with high-density lipoprotein, or HDL-cholesterol, being the good form, and low-density lipoproteins, or LDL-cholesterol, and very low-density lipoproteins, or VLDL-cholesterol, being bad forms directly involved in heart disease. Collectively lowering LDL-cholesterol, VLDL-cholesterol, and other bad forms of cholesterol are a key component in the prevention and management of cardiovascular disease.

Currently in Phase 3 development, mipomersen has been shown in Phase 2 trials to reduce cholesterol and other atherogenic lipids more than 40 percent beyond reductions achieved with standard lipid-lowering drugs, enabling more patients to achieve LDL-cholesterol targets. These trials have shown that treatment with mipomersen is well-tolerated, and that mipomersen has an attractive safety profile, and works equally well in the presence and absence of other lipid-lowering therapies including statins. A weekly injectable therapeutic, mipomersen is being developed primarily for patients at high cardiovascular risk who are unable to achieve target cholesterol levels with statins alone or who are into
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
2. Clinical Update - Debio 0614 (Istaroxime) in Acute Heart Failure
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
6. Anti-Cancer Drug CYT997 Update
7. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
8. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
9. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
10. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
11. Update on Progression of Phosphagenics and Nestle Nutritions Phospha E(R) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets has ... Medical X-ray Film Industry Report 2014" report to ... Global And Chinese Medical X-Ray Film Industry ... the current state of the Global medical X-ray film ... The report provides a basic overview of the industry ...
(Date:7/11/2014)... 2014 On Thursday, July ... the Dow Jones Industrial Average finished the day 0.42% lower ... 0.41%. The losses were broad based as eight out of ... Health Care Sector Index ended the day at 711.88, down ... one month. Investor-Edge has initiated coverage on the following equities: ...
(Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ... ("Biotie") to end the option held by Biotie to ... further development of NRL-1 (intranasal diazepam) for pediatric and ... Over the past year, Biotie has advanced the ... preparation for the pivotal clinical work required for NDA ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... BEIJING, June 22, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical ... ), a leading China-based advanced in-vitro diagnostic ("IVD") ... GP Medical Technologies Co., Ltd. ("GP Medical"), has ... An Healthcare Investment Ltd. ("Da An Health") to ...
... Millstone Medical Outsourcing announced today that the ... online inventory management system.  After several months of ... password-protected system used by medical device manufacturers to ... of the enhanced inventory management system include increased ...
Cached Medicine Technology:China Medical Technologies Announces Strategic Collaboration Between its Subsidiary, GP Medical, and Da An Health 2China Medical Technologies Announces Strategic Collaboration Between its Subsidiary, GP Medical, and Da An Health 3Millstone Medical Outsourcing Introduces Advanced Version of Online Inventory Management System 2
(Date:7/14/2014)... The Encino cosmetic dentist ... Lumineers and porcelain veneers. These restorations are an ... preparation and greater loss of healthy tooth tissue. They ... visible flaws on the tooth. Encino dentist Dr. Mastour ... to ensure they offer the most appropriate treatment recommendations ...
(Date:7/14/2014)... 14, 2014 (HealthDay News) -- Being physically active in ... Alzheimer,s disease and other types of dementia, suggest the ... we found that physical exercise at various levels, especially ... Geda from the Mayo Clinic, said in an Alzheimer,s ... they are not yet conclusive. More research is needed ...
(Date:7/14/2014)... July 14, 2014 ... performance liquid chromatography or UPLC is a ... liquid chromatography that involves the use of ... to separate chromatographic compounds. This highly sensitive ... detection and analysis of chromatography samples. UPLC ...
(Date:7/14/2014)... Huntington Beach, CA (PRWEB) July 14, 2014 ... of thousands of people undergo plastic surgery to reduce ... hit the market, however, eliminates the need to go ... mouth guard that works the jaw muscles, therefore tightening ... of having two chins. , Jawflex is used for ...
(Date:7/14/2014)... NJ (PRWEB) July 14, 2014 ... established global leader in enterprise-class cloud management, governance, ... platforms, today announced AvePoint software will be available ... managed cloud specialist. , The hosting ... to offer the following AvePoint solutions to new ...
Breaking Medicine News(10 mins):Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Staying Active May Help Prevent Dementia 2Health News:Need for Faster Sample Analysis Drives Demand for UPLC, According to New Trend Report Published by Global Industry Analysts, Inc. 2Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 2Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 3
... Speakers ... Exposition (ACE10), June 20-24, in Chicago, Illinois. , ... Denver (Vocus) February 25, 2010 -- Speakers have been ... June 20-24, in Chicago, Illinois. , ,Denis Hayes will be the highlighted speaker at ...
... , ... Examines IT Executive,s Opinions on Outsourcing , ... Westborough, MA (PRWEB) February 25, 2010 -- Advans, a ... that highlight the growing popularity of domestic outsourcing. According to the Advans’ IT Outsourcing ...
... ... New Inguinal Hernia Product Range Freedom-I, with an Aim to Improve Surgical Outcomes and Take ... ... focused on bringing innovations to the field of medical devices. For the past four years ...
... ... for Sports Medicine (AOSSM), in partnership with Genzyme Biosurgery, is pleased to announce a ... of OA progression. , ... Rosemont, IL (Vocus) February 25, 2010 -- The American Orthopaedic Society for ...
... ... feel like they are falling apart at home, psychotherapeutic interventions provide families with a growing ... (PRWEB) ... like they are falling apart at home, psychotherapeutic interventions provide families with a growing array ...
... ... continue to await their orders of Xyngular Xyng™ as Zija,s NEW! ... Xyngular™ to market months before their NEW! Xyng™ product was released ... People from all over the world are calling to become distributors ...
Cached Medicine News:Health News:AWWA Announces ACE10 Speakers 2Health News:Advans Survey Reveals that 75 Percent of Executives Prefer Domestic Outsourcing vs. Offshore 2Health News:Insightra Medical Inc Gains CE Mark on the Freedom(TM) Inguinal Hernia Product Range 2Health News:Insightra Medical Inc Gains CE Mark on the Freedom(TM) Inguinal Hernia Product Range 3Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 2Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 3Health News:New Approaches to Teen Therapy Bring Results 2Health News:New Approaches to Teen Therapy Bring Results 3Health News:New Approaches to Teen Therapy Bring Results 4Health News:New Approaches to Teen Therapy Bring Results 5Health News:Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales 2Health News:Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: